The company focuses on disease-specific 3D protein conformations, which exposes new binding sites (epitopes) not present on the same protein in healthy cells. This allows for highly selective drugs that avoid the toxicity common with targets defined by genetic sequence alone.

The debate isn't about peptides replacing antibodies but about combining them. The future lies in hybrid therapeutics, such as grafting peptides into antibody CDRs or creating fusions that use a peptide for optimal target binding and an antibody scaffold for effector functions, half-life extension, and stability.

The company positions its peptide platform as the ideal middle ground in drug development. They aim to create medicines that are functionally like highly selective, less toxic large biologics (e.g., antibodies) but are structurally designed for the convenience of an oral pill, combining the best attributes of both major drug classes.

The dominance of peptides for GLP-1 therapeutics isn't a failure of antibodies but a success for picking the right tool. Peptides have a natural advantage when the therapeutic strategy involves engineering a natural ligand, making them a better starting point for certain targets like GPCRs.

As AI tools have largely solved the initial design of functional mini-proteins, the critical technical challenge has shifted. The primary bottleneck is now engineering a suitable half-life. In their raw form, these molecules are cleared from the body in 10-20 minutes, necessitating strategies like FC fusions or lipidations to make them therapeutically viable.

Increasing a biologic's binders from two or four to six or twelve is not an incremental improvement. It creates 'emergent properties of scale.' This high valency allows for sophisticated control over 3D spatial geometry at the cell surface and eliminates the design trade-offs inherent in simpler multispecific molecules.

For complex biologics with many binders, chasing astronomical affinity is counterproductive and risks off-tumor toxicity. A better strategy is to use binders with modest affinity and leverage the massive avidity gained from multiple binding sites. This provides a 'finer dial' to tune specificity and improve the therapeutic window.

CEO Jonathan Steckbeck simplifies a complex topic by describing peptides as a "Goldilocks modality." They sit between small molecules (good access, poor specificity) and biologics (poor access, good specificity), ideally offering the best of both worlds for targeted drug delivery.

Antibodies bind to specific amino acid sequences, making them unable to distinguish between a protein's healthy and toxic structural forms. Alt-Pep's synthetic peptides use a complementary structure (alpha-sheet) to selectively bind only the toxic oligomers, enabling both targeted therapy and highly specific diagnostics.